Functional Plasticity of Group II Metabotropic Glutamate Receptors in Regulating Spinal Excitatory and Inhibitory Synaptic Input in Neuropathic Pain

Hong-Yi Zhou, Shao-Rui Chen, Hong Chen, and Hui-Lin Pan

Department of Anesthesiology and Perioperative Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas (H.-Y.Z., S.-R.C., H.C., H.-L.P.); and Program in Neuroscience, University of Texas Graduate School of Biomedical Sciences, Houston, Texas (H.-L.P.)

Received July 19, 2010; accepted October 4, 2010

ABSTRACT

Metabotropic glutamate receptors (mGluRs) are involved in the modulation of synaptic transmission and plasticity. Group II mGluRs in the spinal cord regulate glutamatergic input, but their functional changes in neuropathic pain are not clear. In this study, we determined the plasticity of spinal group II mGluRs in controlling excitatory and inhibitory synaptic transmission and nociception in neuropathic pain. Neuropathic pain was induced by spinal nerve ligation in rats, and whole-cell voltage-clamp recordings of glutamatergic excitatory postsynaptic currents (EPSCs) and spontaneous and miniature GABAergic and glycinergic inhibitory postsynaptic currents (sIPSCs and mIPSCs, respectively) were performed in spinal cord slices. The specific group II mGluR agonist (2S,2’R,3’R)-2-(2’-3’-dicarboxycyclopropyl)glycine (DCG-IV) had a similar inhibitory effect on monosynaptic EPSCs evoked from the dorsal root in sham and nerve-injured rats. However, DCG-IV produced a greater inhibitory effect on evoked polysynaptic EPSCs and the frequency of spontaneous EPSCs in nerve-injured rats than in control rats. Although DCG-IV similarly reduced the frequency of GABAergic sIPSCs and mIPSCs in both groups, it distinctly inhibited the frequency of glycinergic sIPSCs and mIPSCs only in nerve-injured rats. The DCG-IV effect was blocked by the group II mGluR antagonist but not by the N-methyl-D-aspartate receptor antagonist. Strikingly, intrathecal injection of DCG-IV dose-dependently attenuated allodynia and hyperalgesia in nerve-injured rats but produced hyperalgesia in control rats. Our study provides new information that nerve injury up-regulates group II mGluRs present on glutamatergic and glycinergic interneurons in the spinal cord. Activation of group II mGluRs reduces neuropathic pain probably by attenuating glutamatergic and glycinergic input to spinal dorsal horn neurons.

Introduction

Chronic neuropathic pain remains an unmet clinical problem because available treatments have limited efficacy in many patients. Neuropathic pain is typically caused by a lesion or dysfunction of the peripheral or central nervous system. The proposed mechanisms of neuropathic pain include increased primary afferent excitability (Gracely et al., 1992; Matzner and Devor, 1994), increased glutamatergic input to dorsal horn neurons (Kohno et al., 2003; Wang et al., 2007), and diminished GABAergic inhibition caused by a depolarizing shift in the anion gradient of dorsal horn neurons (Coulth et al., 2003, 2005). The dorsal horn of the spinal cord is a crucial site for pain transmission and modulation (Cervero and Iggo, 1980). A better understanding of the cellular and molecular mechanisms that regulate the synaptic transmission in the spinal dorsal horn is critical for developing more effective treatments for neuropathic pain.

Increased glutamatergic synaptic inputs to spinal dorsal horn neurons play a pivotal role in the development and maintenance of central sensitization and neuropathic pain conditions (Kohno et al., 2003; Wang et al., 2007; Zhang et al., 2009). Glutamate is a major excitatory neurotransmitter released from primary afferents and interneurons in the spinal cord.
spinal cord. Glutamate acts on both ionotropic receptors and metabotropic glutamate receptors (mGlRs). mGlRs are involved in synaptic plasticity at various levels of the nervous system (Anwyl, 1999). Eight mGlRs have been cloned and classified into group I (mGlR1 and mGlR5), group II (mGlR2 and mGlR3), and group III (mGlR4, mGlR6, mGlR7, and mGlR8) (Anwyl, 1999; Schoepp et al., 1999). Group I mGlRs are coupled to G_{q/11} proteins, leading to activation of phospholipase C and increased neuronal firing and synaptic transmission. Group II and III mGlRs, however, are typically coupled to inhibitory G_{i/o} proteins, thereby inhibiting cAMP formation and voltage-gated Ca^{2+} channels to reduce neuronal excitability and synaptic transmission (Conn and Pin, 1997; Anwyl, 1999). Group II mGlRs (mGlR2/3) are very difficult to separate from each other by using pharmacological approaches, because their proteins share so much sequence similarity. Group II mGlRs are present in the dorsal root ganglion and spinal superficial dorsal horn (Jia et al., 1999; Carlton et al., 2001), and stimulation of these mGlRs in the spinal cord generally depresses synaptic transmission (Gerber et al., 2000; Zhou et al., 2007). We have demonstrated that activation of group I and group III mGlRs has distinct effects on synaptic transmission in the spinal dorsal horn in neuropathic pain (Chen and Pan, 2005; Zhang et al., 2009; Li et al., 2010). In contrast, the nerve injury-induced changes in group II mGlR function in the spinal dorsal horn and their functional significance in neuropathic pain is still not clear.

We, therefore, conducted the present study to determine the functional plasticity of group II mGlRs in the control of excitatory and inhibitory synaptic transmission in the spinal dorsal horn in a rat model of neuropathic pain. Our findings provide new information that nerve injury increases the function of group II mGlRs located on glutamatergic and glycinergic interneurons in the spinal dorsal horn. Furthermore, we found that stimulation of spinal group II mGlRs attenuates neuropathic pain, probably by preferential inhibition of synaptic glutamate and glycine release to dorsal horn neurons.

### Materials and Methods

#### Animal Model of Neuropathic Pain and Intrathecal Cannulation.
Male Sprague-Dawley rats (180–200 g; Harlan, Indianapolis, IN) were used in this study. All surgical preparation and experimental protocols were approved by the Animal Care and Use Committee of the University of Texas MD Anderson Cancer Center and conformed to the National Institutes of Health guidelines for the ethical use of animals. L5 and L6 spinal nerve ligation was used as an experimental model of neuropathic pain in our study (Chen and Chung, 1992). We induced anesthesia with 2 to 3% isoflurane and 95% O2 and 5% CO2 at 34°C maintained by an inline solution heater and a temperature controller. The neurons in lamina II were identified under a fixed-stage microscope (BX50WI; Olympus, Tokyo, Japan) with differential interference contrast/infrared illumination. The electrode for the whole-cell recordings was pulled from borosilicate glass capillaries with a puller (Sutter Instrument Company, Novato, CA). The impedance of the pipette was 5 to 10 MΩ when filled with internal solution for recording excitatory postsynaptic currents (EPSCs) containing 135 mM K-gluconate, 2 mM KCl, 2 mM MgCl2, 0.5 mM CaCl2, 5 mM HEPES, 5 mM EGTA, 5 mM ATP-Mg, 0.5 mM Na-GTP, 1 mM guanosine 5′-O-(2-thiodiphosphate) (GDP-β-S), and 10 mM lidocaine N-ethyl bromide (QX314) adjusted to pH 7.2 to 7.4 with 1 M KOH (290–300 mOsM). The impedence of the pipette was 3 to 5 MΩ when filled with internal solution for recording inhibitory postsynaptic currents (IPSCs) containing 110 mM CsSO4, 5 mM KCl, 2 mM MgCl2, 0.5 mM CaCl2, 5 mM HEPES, 5 mM EGTA, 5 mM ATP-Mg, 0.5 mM Na-GTP, 1 mM GDP-β-S, and 10 mM QX314 adjusted to pH 7.2 to 7.4 with 1 M CsOH (290–300 mOsM). GDP-β-S was added to the internal solution to block the possible postsynaptic effect of the group II mGlR agonists. QX-314 was added into the internal solution to suppress the action potential generation from the recorded cell.

All recordings were performed on lamina II neurons at the L5 spinal level ipsilateral to the surgery side. The glutamatergic EPSCs were recorded at a holding potential of −60 mV in the presence of 2

### Behavioral Assessment of Nociception in Rats.
To quantify tactile allodynia, rats were placed in individual plastic boxes on a mesh floor and allowed to acclimate for 30 to 45 min. A series of calibrated von Frey filaments was applied perpendicularly to the plantar surface of the hindpaw with sufficient force to bend the filaments for 5 s. Brisk paw withdrawal or flinching was considered a positive response. In the absence of a response, the filament of next greater force was applied. If a response occurred, the filament of next lower force was applied. The tactile stimulus producing a 50% likelihood of withdrawal was determined by using the “up-down” calculating method (Chaplan et al., 1997; Chen et al., 2000). Tactile allodynia was confirmed in all rats subjected to spinal nerve ligation.

The paw pressure test was used to quantify the mechanical nociceptive threshold of the hindpaw (mechanical hyperalgesia) (Chen and Pan, 2006; Chen et al., 2009b). Nociceptive thresholds, expressed in grams, were measured with an analgesimeter (Ugo Basile, Varese, Italy). The test was performed by applying a pressure stimulus to the hindpaw. When a pedal that activates a motor was pressed, the force increased on a linear scale at a constant rate. When the animal showed pain by withdrawal of the paw or vocalization, the pedal was released and the nociceptive pain threshold was read on a scale.
µM strychnine and 10 µM bicuculline. Signals were recorded with an amplifier (MultiClamp 700B; Molecular Devices, Sunnyvale, CA), filtered at 1 to 2 kHz, digitized at 10 kHz, and stored into a computer with pCLAMP 9.2 (Molecular Devices). The evoked EPSCs (eEPSCs) of lamina II neurons were induced by electrical stimulation (0.8 mA, 0.2 ms, 0.2 Hz) of the dorsal root (Zhou et al., 2005a; Zhang et al., 2009). Because the retained dorsal root was very short, we did not measure the conduction velocity of afferent fibers stimulated. At the stimulation intensity used, both A- and C-afferent fibers that were in close contact with the electrode tip were stimulated (Wang et al., 2007; Zhou et al., 2010). The eEPSCs were considered monosynaptic if the latency was constant after electrical stimulation (0.2 Hz) and if no conduction failure or increased latency occurred when stimulation frequency was increased to 20 Hz. In contrast, the latency of polysynaptic eEPSCs varied and conduction failure occurred when the stimulation frequency was increased to 20 Hz (Li et al., 2010; Zhou et al., 2010).

GABAergic inhibitory postsynaptic currents (IPSCs) were recorded at a holding potential of 0 mV in the presence of 20 µM 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX) and 2 µM strychnine. Glycineric IPSPCs were recorded in the presence of 20 µM CNQX and 10 µM bicuculline (Zhou et al., 2007, 2008b). To record the miniature EPSCs (mEPSPCs) and miniature IPSCs (mIPSPCs), 1 µM tetrodotoxin was added to the perfusion solution. DCG-IV and (2S)-α-ethylglutamic acid (EGLU) were purchased from Tocris Bioscience (Ellisville, MO). GDP-β-S, strychnine, CNQX, 2-amino-5-phosphonopentanoic acid (AP-5), and bicuculline were obtained from Alomone Labs (Jerusalem, Israel). Drugs were dissolved in Krebs’ solution and perfused into the slice chamber by using syringe pumps.

Data Analysis. Data are presented as the means ± S.E.M. The effects of DCG-IV and EGLU on the paw withdrawal thresholds were compared by using repeated measures analysis of variance followed by Tukey’s post hoc test. The sEPSPCs, mEPSPCs, sIPSPCs, and mIPSPCs were analyzed off-line with a peak detection program (MiniAnalysis; Synaptosoft, Decatur, GA). Measurements of the amplitude and frequency of sEPSPCs, mEPSPCs, sIPSPCs, and mIPSPCs were performed during control, drug application, and recovery. The cumulative probability of the amplitude and interevent interval of sEPSPCs, mEPSPCs, sIPSPCs, and mIPSPCs was compared by using the Komogorov-Smirnov test, which estimates the probability that two cumulative distributions are similar. Analyses of the effect of DCG-IV on the amplitude of eEPSPCs were performed by using Clampfit 9.2 (Molecular Devices). Neurons were considered to be inhibited by DCG-IV if the amplitude of eEPSPCs was reduced >15%. Differences were determined by repeated measures analysis of variance or two-way analysis of variance. *P < 0.05 was considered to be statistically significant.

Results

Effect of DCG-IV on Glutamatergic Monosynaptic and Polysynaptic EPSPCs in Nerve-Injured Rats. To determine the role of group II mGluRs in the control of glutamatergic input from primary afferents to dorsalhorn neurons in sham and nerve-injured rats, we tested the effect of the group II mGluR agonist DCG-IV on monosynaptic eEPSPCs elicited from the dorsal root. DCG-IV is a highly specific agonist of mGluR2/3 (Ishida et al., 1993a; Hayashi et al., 1994; Gerber et al., 2000). LY354740 has an affinity in the nanomolar range for group II mGluRs (Schoppa and Westbrook, 1997; Monn et al., 1999; Schoepp et al., 1999). However, we did not choose LY354740 for our study because it has a weak agonist effect on mGluR6 and mGluR8 (Wu et al., 1998; Monn et al., 1999). In nerve-injured rats, the baseline amplitude of monosynaptic eEPSPCs of lamina II neurons elicited from the dorsal root (i.e., glutamatergic input from primary afferents) was significantly larger than that in sham rats (415.80 ± 32.58 versus 324.00 ± 36.48 pA; Fig. 1, A–C). Bath application of DCG-IV (1–10 µM, applied for 3 min) significantly reduced the peak amplitude of monosynaptic eEPSPCs in a concentration-dependent manner in both sham rats (6 of 20 cells, 30%) and nerve-injured rats (10 of 19 cells, 52.6%); P > 0.05, Fisher’s exact test) (Fig. 1, A–C).

When the effect of DCG-IV on eEPSPCs was normalized to baseline, the degree of inhibition of the amplitude of monosynaptic eEPSPCs by DCG-IV was similar in both groups (Fig. 1C). DCG-IV (0.3–10 µM) had no significant effect on monosynaptic eEPSPCs in the rest of the neurons tested in either the control group (14 of 20 neurons) or nerve-injured rats (9 of 19 neurons).

The baseline amplitude of polysynaptic eEPSPCs from the dorsal root (i.e., mixed glutamatergic input from primary afferents and interneurons) was also significantly larger in the nerve-injured group than in the sham group (275.08 ± 22.73 versus 251.03 ± 13.63 pA; Fig. 1D). DCG-IV (1–10 µM) inhibited the amplitude of polysynaptic eEPSPCs in a concentration-dependent fashion in both the sham and nerve-ligated rats (Fig. 1D). Although the incidence of inhibition of polysynaptic eEPSPCs of lamina II neurons by DCG-IV was similar in the sham (10 of 15 neurons, 66.7%) and nerve-injured (9 of 14 neurons, 64.3%) groups, the magnitude of inhibition of the amplitude of polysynaptic eEPSPCs by DCG-IV was significantly greater in nerve-injured rats than in sham control rats (Fig. 1D). At 3 µM, DCG-IV inhibited 36.6 ± 3.3 and 19.7 ± 4.1% of the amplitude of polysynaptic eEPSPCs in nerve-injured and control rats, respectively.

Some studies have reported that DCG-IV, at a high concentration, might produce its effect via activation of NMDA receptors (Ishida et al., 1993b; Breakwell et al., 1997). To determine whether NMDA receptors are involved in the inhibitory effect of DCG-IV on synaptic transmission in the spinal cord, we tested the effect of DCG-IV in the presence of AP-5, the specific NMDA receptor antagonist in a separate group of lamina II neurons showing responses to 3 and 10 µM DCG-IV. In the presence of 50 µM AP-5, bath application of DCG-IV inhibited the amplitude of monosynaptic and polysynaptic eEPSPCs to a degree that was similar to DCG-IV alone in nerve-injured rats (Fig. 1E). These results suggest that glutamatergic input from primary afferents to spinal dorsal horn neurons is augmented after nerve injury. Furthermore, our data suggest that nerve injury increases the activity of group II mGluRs expressed on glutamatergic interneurons in the spinal dorsal horn.

Effect of DCG-IV on Glutamatergic sEPSPCs and mEPSPCs in Control and Nerve-Injured Rats. To further determine the role of group II mGluRs in the control of glutamatergic transmission in the spinal dorsal horn, we examined the effect of DCG-IV on glutamatergic sEPSPCs and mEPSPCs in lamina II neurons of sham and nerve-injured rats. There were no significant differences in the baseline amplitude (18.81 ± 1.45 pA) or frequency (7.54 ± 0.83 versus 7.92 ± 0.34 Hz) of sEPSPCs between the sham and nerve-injured groups (Fig. 2, A–E). Bath application of 3 µM DCG-IV for 3 min significantly inhibited the frequency, but not the amplitude, of sEPSPCs in all 13 neurons from sham rats and all 16 neurons from nerve-injured rats.

The baseline frequency of sEPSPCs, mEPSPCs, sIPSPCs, and mIPSPCs was compared by using repeated measures analysis of variance followed by Tukey’s post hoc test. The sEPSPCs, mEPSPCs, sIPSPCs, and mIPSPCs were compared by using the cumulative distribution functions in the spinal dorsal horn. Further, our data suggest that nerve injury increases the activity of group II mGluRs expressed on glutamatergic interneurons in the spinal dorsal horn.
rats (Fig. 2, A-F). The cumulative probability analysis of sEPSCs revealed that the distribution pattern of the inter-event interval of sEPSCs was shifted toward the right in response to DCG-IV (Fig. 2, C and D). When the effect of DCG-IV on sEPSCs was normalized to baseline, the magnitude of inhibition of the sEPSC frequency by DCG-IV was significantly greater in nerve-injured rats than in sham control rats (Fig. 2F). In sham and nerve-injured groups, bath application of EGLU (200 nM), a highly specific group II mGluR antagonist (Jane et al., 1996; Schoepp et al., 1999), for 3 min alone had no significant effect on sEPSCs. EGLU completely blocked the inhibitory effect of DCG-IV on the frequency of sEPSCs in both groups (5 cells in each group; Fig. 2, A and B). These data provide further evidence that nerve injury increases the activity of group II mGluRs expressed on glutamatergic interneurons in the spinal dorsal horn.

There were no significant differences in the baseline amplitude (19.64 ± 1.98 versus 17.47 ± 1.59 pA) or frequency (5.86 ± 0.60 versus 6.09 ± 0.49 Hz) of glutamatergic mEPSCs between the sham and nerve-injured groups (Fig. 2G). Bath application of 3 μM DCG-IV also significantly inhibited the frequency, but not the amplitude, of mEPSCs in all 10 neurons from sham rats and all 10 neurons from nerve-injured rats. The inhibitory effect of DCG-IV on the frequency of mEPSCs was similar in both groups (Fig. 2, G and H).

**Effect of DCG-IV on GABAergic sIPSCs and mIPSCs of Lamina II Neurons in Control and Nerve-Injured Rats.**

The basal frequency (1.13 ± 0.15 versus 1.25 ± 0.14 Hz) of GABAergic sIPSCs of lamina II neurons in nerve-injured rats was similar to that in sham rats (Fig. 3). However, the amplitude of GABAergic sIPSCs in the nerve-injured group (13.29 ± 0.81 pA) was significantly smaller than that in the sham group (15.86 ± 1.21 pA; Fig. 3F). DCG-IV (0.3–10 μM) decreased the frequency, but not the amplitude, of GABAergic sIPSCs in a concentration-dependent manner in all 10 neurons from the sham control group and all 12 neurons from the nerve-ligated group (Fig. 3E). The cumulative probability analysis of GABAergic sIPSCs revealed that the distribution pattern of the inter-event interval of sIPSCs was shifted toward the right in response to DCG-IV. However, the inhibitory effect of DCG-IV on the frequency of GABAergic sIPSCs did not differ significantly between the two groups.

The baseline frequency (0.92 ± 0.06 versus 0.96 ± 0.09 Hz)
of GABAergic mIPSCs was also similar in sham and nerve-injured rats (Fig. 4). However, the amplitude of GABAergic mIPSCs was significantly reduced in the nerve-injured group (10.59 ± 0.42 pA) compared with that in the sham control group (14.15 ± 1.76 pA) (Fig. 4F). Bath application of 3 μM DCG-IV significantly decreased the frequency, but not the amplitude, of mIPSCs in all nine cells from the sham control group and all 12 cells from the nerve-ligated group (Fig. 4E). The inhibitory effect of DCG-IV on the frequency of GABAergic mIPSCs did not differ significantly between the two groups. It is noteworthy that 3 μM DCG-IV inhibited the frequency of sIPSCs more than that of mIPSCs in both groups. These data suggest that, although nerve injury attenuates GABAergic inhibitory input to spinal dorsal horn neurons, the activity of group II mGluRs expressed on GABAergic interneurons is not altered in this animal model of neuropathic pain.

Effect of DCG-IV on Glycinergic sIPSCs and mIPSCs of Lamina II Neurons in Control and Nerve-Injured Rats. The baseline frequency of glycinergic sIPSCs of lamina II neurons did not differ significantly between the sham control and nerve-injured groups (Fig. 5). However, the baseline amplitude of glycinergic sIPSCs was significantly reduced in nerve-injured rats compared with that in sham rats (Fig. 5F). DCG-IV (0.3–10 μM) profoundly decreased the frequency, but not the amplitude, of glycinergic sIPSCs in a concentration-dependent manner in all eight cells from the nerve-ligated group (Fig. 5E). In contrast, DCG-IV had no significant effect on glycinergic sIPSCs in all 10 neurons from the sham control group (Fig. 5E). In another group of lamina II neurons in nerve-ligated rats, bath application of 50 μM AP-5 did not affect the inhibitory effect of DCG-IV (3 or 10 μM) on the frequency of glycinergic sIPSCs (Fig. 5F).

Furthermore, the frequency of glycinergic mIPSCs of lamina II neurons did not differ significantly between the sham control and nerve-injured groups (Fig. 6). However, the baseline amplitude of glycinergic mIPSCs was significantly reduced in nerve-injured rats compared with that in sham rats (Fig. 6F). Bath application of 3 μM DCG-IV significantly decreased the frequency, but not the amplitude, of mIPSCs in all 11 cells from the nerve-ligated group (Fig. 6E). In contrast, DCG-IV had no significant effect on the frequency or
Fig. 3. Effects of DCG-IV on GABAergic sIPSCs of lamina II neurons in sham and nerve-injured rats. A and B, original traces of GABAergic sIPSCs during control, application of 3 μM DCG-IV, and washout in one sham and one nerve-injured rat. C and D, cumulative probability plots of GABAergic sIPSCs of the same neuron in A and B showing the distribution of the amplitude and interevent interval during control, application of DCG-IV, and washout. E, summary data comparing the baseline frequency and the effect of DCG-IV on the frequency of GABAergic sIPSCs in sham and nerve-injured rats. *, P < 0.05 compared with the baseline control. F, summary data comparing the baseline amplitude and the effect of DCG-IV on the amplitude of GABAergic sIPSCs in sham and nerve-injured rats. #, P < 0.05 compared with the corresponding value in the control group. Data presented are the means ± S.E.M.

Fig. 4. Effects of DCG-IV on GABAergic mIPSCs of lamina II neurons in sham and nerve-injured rats. A and B, original traces of GABAergic mIPSCs during control, application of 3 μM DCG-IV, and washout in one sham and one nerve-injured rat. C and D, cumulative probability plots of GABAergic mIPSCs of the same neuron in A and B showing the distribution of the amplitude and interevent interval during control, application of DCG-IV, and washout. E, summary data comparing the baseline frequency of GABAergic mIPSCs and the effect of 3 μM DCG-IV on the frequency of GABAergic mIPSCs in sham and nerve-injured rats. *, P < 0.05 compared with the baseline control. F, summary data comparing the baseline amplitude and the effect of 3 μM DCG-IV on the amplitude of GABAergic mIPSCs in sham and nerve-injured rats. #, P < 0.05 compared with the corresponding value in the control group. Data are presented as means ± S.E.M.
amplitude of glycinergic mIPSCs in all 11 neurons from the sham control group (Fig. 6E). It is noteworthy that DCG-IV (3 μM) reduced the sIPSC frequency more than the frequency of glycinergic mIPSCs in nerve-injured rats (Fig. 5E). These findings suggest that nerve injury reduces glycinergic input to spinal dorsal horn neurons and induces the expression of group II mGluRs on glycinergic interneurons and their terminals in the spinal dorsal horn.

**Effect of Intrathecal Injection of DCG-IV on Tactile Allodynia and Hyperalgesia in Nerve-Injured Rats.** To determine how group II mGluR stimulation affects nociceptive transmission at the spinal level, we compared the potential antinociceptive effects of intrathecal injection of DCG-IV in control and nerve-injured rats. Intrathecal injection of 0.02 to 0.5 μg of DCG-IV significantly increased the paw withdrawal threshold in response to application of von Frey filaments in nerve-ligated rats in a dose-dependent manner (n = 7 rats in each dose group; Fig. 7A). These doses of DCG-IV were selected in our preliminary experiments. The maximal effect of DCG-IV appeared within 30 min and gradually subsided within 150 min after intrathecal administration. To ensure the specific effect of DCG-IV on group II mGluRs, EGLU (10 μg), a specific antagonist for group II mGluRs, was given intrathecally 15 min before 0.5 μg of DCG-IV was injected in another seven rats. Intrathecal injection of 10 μg of EGLU did not significantly change the baseline withdrawal threshold (data not shown). EGLU abolished the effect of DCG-IV on tactile allodynia in nerve-injured rats (Fig. 7A).

Intrathecal administration of DCG-IV also dose-dependently increased the paw withdrawal threshold in response to the noxious pressure stimulus in nerve-injured rats (Fig. 7B). We were surprised to find that intrathecal injection of DCG-IV significantly reduced the pressure withdrawal threshold in sham rats in a dose-dependent manner (Fig. 7C). In both groups, the peak effect of DCG-IV appeared within 30 min after intrathecal injection, and the effect lasted for approximately 150 min. Intrathecal pretreatment with 10 μg of...
EGLU completely blocked the effect of 0.5 μg of DCG-IV on the pressure withdrawal threshold in both sham and nerve-injured rats (Fig. 7, B and C). In addition, to determine whether the pronociceptive effect of DCG-IV resulted from NMDA receptor activation in sham control rats, we examined the effect of DCG-IV in the presence of the NMDA receptor antagonist AP-5 in another seven sham rats. In this protocol, we injected 10 μg of AP-5 intrathecally 15 min before administration of 0.5 μg of DCG-IV. Intrathecal injection of 0.5 μg of DCG-IV similarly reduced the pressure withdrawal threshold in the presence of AP-5 (Fig. 7C).

Discussion

In this study, we determined the functional plasticity of spinal group II mGluRs in the regulation of excitatory and inhibitory synaptic transmission in neuropathic pain. We found that the amplitude of monosynaptic and polysynaptic eEPSCs evoked from primary afferents was significantly larger in spinal nerve-injured rats than in control rats. This finding suggests that nerve injury increases the glutamatergic input from primary afferents to spinal dorsal horn neurons. Our results are consistent with previous studies showing augmented glutamatergic input from primary afferents in neuropathic pain induced by nerve ligation and diabetic neuropathy in rats (Kohno et al., 2003; Wang et al., 2007; Zhang et al., 2009). The study by Moore et al. (2002) did not find any difference in the amplitude of primary afferent-evoked EPSCs of lamina II neurons in nerve injury models. However, there are some major technical differences between their studies and ours (e.g., suction versus bipolar electrode, long versus short dorsal root, blind versus visualized recording, and recording at L4 versus L5/L6 levels). Increased excitability of primary afferent nerves and ectopic discharges from injured afferent nerves (Gracely et al., 1992; Matzner and Devor, 1994) can result in enhanced glutamatergic input from primary afferents. In addition, nerve injury reduces the expression and activity of voltage-activated and Ca2+-activated K+ channels in primary sensory neurons (Everill and Kocsis, 1999; Kim et al., 2002; Sarantopoulos et al., 2007; Chen et al., 2009a).

GABA and glycine are the two major inhibitory neurotransmitters in the normal spinal cord. Reduced GABA- and glycine-mediated inhibition (disinhibition) may also contribute to the hyperexcitability of spinal dorsal horn neurons and pain sensitivity. For instance, blocking spinal GABA_A receptors produces tactile allodynia in rats (Sorkin et al., 1998). In addition, blockade of glycine receptors in the spinal cord leads to hypersensitivity of spinal dorsal horn neurons and allodynia in rats (Yaksh, 1989). We found that the baseline amplitude, but not the frequency, of GABAergic mIPSCs and glycine IPSCs was significantly smaller in nerve-injured rats than in control rats. In addition, the reduction in the amplitude of glycine IPSCs seemed to be greater than that of GABAergic IPSCs in the spinal cord of nerve-injured rats. Some studies reported that the number of GABA-immunoreactive neurons in the spinal dorsal horn is reduced after nerve injury (Castro-Lopes et al., 1993; Ibuki et al., 1997; Moore et al., 2002). However, other studies have shown that nerve injury does not cause any significant loss of
The inclusion of 10 μg of AP-5 did not alter the effect of DCG-IV (0.5 μg) in sham and nerve-injured rats. Note that intrathecal pretreatment with 10 μg of AP-5 abolished the effect of DCG-IV on the nociceptive withdrawal threshold in response to a noxious pressure stimulus in sham and nerve-injured rats. Intrathecal pretreatment with 10 μg of AP-5 did not alter the effect of DCG-IV (0.5 μg) on the withdrawal threshold in sham control rats. Intrathecal pretreatment with 10 μg of AP-5 did not alter the effect of DCG-IV (0.5 μg) on the withdrawal threshold in sham control rats. Data presented as mean ± S.E.M. (n = 7 rats in each dose group). * P < 0.05 compared with the respective baseline control (time 0).

Fig. 7. Time course of the effect of intrathecal injection of DCG-IV on the paw withdrawal thresholds in sham and nerve-injured rats. A, effect of intrathecal injection of DCG-IV on tactile allodynia measured with von Frey filaments in nerve-injured rats. B, effect of intrathecal injection of DCG-IV on hyperalgesia tested with a noxious pressure stimulus in nerve-injured rats. C, effect of intrathecal injection of DCG-IV on the nociceptive withdrawal threshold in response to a noxious pressure stimulus in sham control rats. Intrathecal pretreatment with 10 μg of EGLU abolished the effect of DCG-IV on the paw withdrawal thresholds in both sham and nerve-injured rats. Note that intrathecal pretreatment with 10 μg of AP-5 did not alter the effect of DCG-IV (0.5 μg) on the withdrawal threshold in sham control rats. Data presented as mean ± S.E.M. (n = 7 rats in each dose group). * P < 0.05 compared with the respective baseline control (time 0).

GABAergic and glycinergic neurons in the spinal dorsal horn (Polgár et al., 2003, 2005; Hermanns et al., 2009). Whereas ionotropic glutamate receptors are responsible for fast excitatory synaptic transmission, mGluRs have an important role in synaptic modulation throughout the central nervous system. Activation of group II mGluRs generally depresses glutamatergic and GABAergic transmission in the normal spinal cord (Gerber et al., 2000; Zhou et al., 2007), but the functional plasticity of spinal group II mGluRs in the regulation of synaptic transmission in neuropathic pain remains unclear. It has been shown that systemic administration of the group II mGluR agonist (2R,4R)-amino-pyrrolidine-2,4-dicarboxylic acid attenuates tactile allodynia induced by nerve injury in rats (Fisher et al., 2002). Others have reported that although intraperitoneal injection of the group II mGluR agonist (1S,2R,5R,6R)-2-amino-4-oxabicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY379268) reduces allodynia, it has no significant effect on heat and mechanical hyperalgesia induced by spinal nerve ligation in rats (Simmons et al., 2001). However, the direct spinal effects of the group II mGluR agonists on neuropathic pain and the associated underlying synaptic mechanisms remain to be investigated. We found that spinally administered DCG-IV dose-dependently attenuated allodynia and hyperalgesia in nerve-injured rats. Unexpectedly, we found that DCG-IV dose-dependently decreased the paw withdrawal threshold in response to noxious mechanical stimulus (i.e., hyperalgesia) in control rats. In addition to their presence on primary afferent terminals (Gerber et al., 2000; Carlton et al., 2001), group II mGluRs exist on GABAergic interneurons in the spinal cord (Zhou et al., 2007). The inhibitory effect of the group II mGluR agonist on GABAergic inhibitory input to spinal dorsal horn neurons may explain the pronociceptive effect of DCG-IV in control animals. DCG-IV produced a similar degree of inhibition of the monosynaptic eEPSCs evoked from the dorsal root in nerve-injured and control rats, suggesting that peripheral nerve injury had no significant effect on the function of group II mGluRs expressed on primary afferent terminals. However, DCG-IV had a significantly greater inhibitory effect on polysynaptic eEPSCs and sEPSCs in nerve-injured rats than in control rats. Our results are consistent with a study showing that the group II mGluR agonist reduces noxious stimulus-evoked glutamate release, measured using microdialysis and high-performance liquid chromatography techniques, in the spinal cord of rats with neuropathic pain (Kumar et al., 2010). It should be noted that potential changes in postsynaptic group II mGluRs in neuropathic pain cannot be ruled out because of the use of GDP-β-S in the internal recording solution in our experiments. Our study suggests that activation of group II mGluRs inhibits nociceptive transmission by reducing glutamatergic input to spinal dorsal horn neurons in a neuropathic pain state.

Another salient finding of our study is that stimulation of group II mGluRs with DCG-IV decreased the frequency of glycinergic sIPSCs and mIPSCs of dorsal horn neurons only in nerve-injured rats. We also found that DCG-IV produced much larger inhibition of glycinergic sIPSCs than glycinergic mIPSCs in nerve-injured rats. Thus, it seems that nerve injury up-regulates group II mGluRs on both somatodendritic sites and presynaptic terminals of glycinergic interneurons in the spinal dorsal horn. The mechanisms underlying the distinct effect of the group II mGluRs on glycinergic input in nerve-injured rats are not clear. It is possible that nerve injury may selectively up-regulate group II mGluRs on a subpopulation of GABAergic-glycinergic interneurons in the spinal cord through increased excitability of a particular group of primary afferents (Lu and Perl, 2003). Immunocytochemical results suggest that GABA- and glycine-like immunoreactivities are often colocalized in the spinal dorsal horn (Todd and Sullivan, 1990; Todd, 1996). However, corelease of GABA and glycine from the same synaptic terminal in the superficial dorsal horn seems rare because direct paired recordings of dorsal horn neurons show that the
IPSCs evoked from a single presynaptic terminal are mediated by either GABAergic or glycine receptors but not by both (Lu and Perl, 2003; Santos et al., 2007). In addition, our previous studies have shown that muscarinic receptor subtypes and group II and III mGluRs are differentially involved in the control of GABAergic and glycineric input in the spinal dorsal horn (Zhang et al., 2005; Wang et al., 2006; Zhou et al., 2007, 2008b). It has been shown that down-regulation of the K⁺/Cl⁻ cotransporter-2 and an increase in intracellular chloride concentrations of dorsal horn neurons after sciatic nerve injury can lead to paradoxical excitation and increased firing activity of dorsal horn neurons in response to GABA (Coulle et al., 2003). Hence, inhibition of abnormal GABAergic and glycineric input by activation of group II mGluRs may reduce paradoxical excitation of spinal dorsal horn neurons by GABA and glycine to reduce neuropathic pain. Nevertheless, it is not certain whether the inhibitory effect of DCG-IV on GABAergic and glycineric input to dorsal horn neurons contributes to the antinoceptive effect of spinally administered DCG-IV on neuropathic pain. In addition, because glycine is a coagonist of NMDA receptors, reduced synaptic glycine release by activation of group II mGluRs may attenuate neuropathic pain by inhibiting the activity of NMDA receptors in the spinal cord induced by nerve injury.

It has been reported that higher concentrations of DCG-IV could stimulate NMDA receptors (Ishida et al., 1993b; Breakwell et al., 1997). Because activation of presynaptic NMDA receptors increases neurotransmitter release in the spinal cord (Liu et al., 1997; Zhou et al., 2010), the inhibitory effects of DCG-IV on synaptic transmission observed in our study cannot be explained by its effect on NMDA receptors. In addition, it has been shown that 5 μM DCG-IV does not produce any significant change in intracellular Ca²⁺ in all superficial dorsal horn neurons in rats (Heinke and Sandkühler, 2007), suggesting that this concentration of DCG-IV does not activate NMDA receptors in the spinal dorsal horn. Nevertheless, it could be argued that the observed pronociceptive effect of DCG-IV in sham control rats may result from stimulation of NMDA receptors. However, we found that blocking the NMDA receptors with AP-5 did not affect the spinal effect of DCG-IV on the pressure withdrawal threshold in sham control rats. Furthermore, we found that AP-5 failed to alter the inhibitory effects of DCG-IV on monosynaptic and polysynaptic eEPSCs and glycineric sIPSCs in nerve-injured rats. Therefore, the spinal effects of DCG-IV on synaptic transmission and nociception observed in our study are unlikely to be caused by the activation of NMDA receptors.

In summary, we demonstrated in this study that activation of group II mGluRs at the spinal level produces a distinct effect on nociception in control and nerve-injured rats. Our findings suggest that nerve injury up-regulates group II mGluRs present on glutamatergic and glycineric interneurons in the spinal dorsal horn in neuropathic pain. Therefore, activation of group II mGluRs could reduce neuropathic pain by selectively attenuating glutamatergic input and synaptic glycine release to spinal dorsal horn neurons. Our findings provide new information about the plasticity of group II mGluRs in the spinal dorsal horn in neuropathic pain. These functional changes in group II mGluRs provide a rationale for the use of spinally administered group II mGluR agonists to treat neuropathic pain.


Address correspondence to: Dr. Hui-Lin Pan, Department of Anesthesiology and Perioperative Medicine, Unit 110, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030. E-mail: huilinpan@mdanderson.org